Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

References

• SiegelRDeSantisCVirgoKCancer treatment and survivorship statistics, 2012CA Cancer J Clin201262422024122700443
   PubMed Web of Science ®Google Scholar
• HarschmanLCChoueiriTKTargeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinomaCancer J201319431632323867513
   PubMed Web of Science ®Google Scholar
• RankinEBFuhKCCastelliniLDirect regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and METProc Natl Acad Sci U S A201411137133731337825187556
   PubMed Web of Science ®Google Scholar
• Bommi-ReddyAAlmecigaISawyerJKinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screenProc Natl Acad Sci USA200810543164841648918948595
   PubMed Web of Science ®Google Scholar
• GibneyGTAzizSACampRLc-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinomaAnn Oncol201324234334923022995
   PubMed Web of Science ®Google Scholar
• KoochekpourSJeffersMWangPHThe von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cellsMol Cell Biol19991995902591210454537
   PubMed Web of Science ®Google Scholar
• SaylorPJEscudierBMichaelsonMDImportance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapyClin Genitourin Cancer2012102778322382009
   PubMed Web of Science ®Google Scholar
• FernandoNTKochMRothrockCTumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factorsClin Cancer Res20081451529153918316578
   PubMed Web of Science ®Google Scholar
• EderJPVande WoudeGFBoernerSALoRussoPMNovel therapeutic inhibitors of the c-Met signaling pathway in cancerClin Cancer Res20091572207221419318488
   PubMed Web of Science ®Google Scholar
• GarajováIGiovannettiEBiascoGc-Met as a target for personalized therapyTransl Oncogenomics20157suppl 1133126628860
   PubMedGoogle Scholar
• Pàez-RibesMAllenEHudockJAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell200915322023119249680
   PubMed Web of Science ®Google Scholar
• MarounCRRowlandsTThe Met receptor tyrosine kinase: a key player in oncogenesis and drug resistancePharmacol Ther2014142331633824384534
   PubMed Web of Science ®Google Scholar
• AlbigesLGueganJLe FormalAMET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression arrayClin Cancer Res201420133411342124658158
   PubMed Web of Science ®Google Scholar
• GiubellinoALinehanWMBottaroDPTargeting the Met signaling pathway in renal cancerExpert Rev Anticancer Ther20099678579319496715
   PubMed Web of Science ®Google Scholar
• FayAPSignorettiSChoueiriTKMET as a target in papillary renal cell carcinomaClin Cancer Res201420133361336324812413
   PubMed Web of Science ®Google Scholar
• ChoueiriTKVaishampayanURosenbergJEPhase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaJ Clin Oncol201331218118623213094
   PubMed Web of Science ®Google Scholar
• CiamporceroEMilesKMAdelaiyeRCombination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma modelsMol Cancer Ther201514110111025381264
   PubMed Web of Science ®Google Scholar
• ShojaeiFLeeJHSimmonsBHHGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumorsCancer Res20107024100901010020952508
   PubMed Web of Science ®Google Scholar
• YakesFMChenJTanJCabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthMol Cancer Ther201110122298230821926191
   PubMed Web of Science ®Google Scholar
• AftabDTMcDonaldDMMET and VEGF: synergistic targets in castration-resistant prostate cancerClin Transl Oncol2011131070370921975330
   PubMed Web of Science ®Google Scholar
• GordonMSVogelzangNJSchoffskiPActivity of cabozantinib (XL184) in soft tissue and bone: results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumorsJ Clin Oncol201129suppl abstract 3010196s
   Google Scholar
• KnudsenBSGmyrekGAInraJHigh expression of the Met receptor in prostate cancer metastasis to boneUrology20026061113111712475693
   PubMed Web of Science ®Google Scholar
• GranoMGalimiFZamboninGHepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitroProc Natl Acad Sci U S A19969315764476488755529
   PubMed Web of Science ®Google Scholar
• DaiJZhangHKaratsinidesACabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesionsClin Cancer Res201420361763024097861
   PubMed Web of Science ®Google Scholar
• ChoueiriTKEscudierBPowlesTCabozantinib versus everoli-mus in advanced renal-cell carcinomaN Engl J Med2015373191814182326406150
   PubMed Web of Science ®Google Scholar
• KurzrockRShermanSIBallDWActivity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancerJ Clin Oncol201129192660266621606412
   PubMed Web of Science ®Google Scholar
• ChoueiriTKPalSKMcDermottDFA phase I study of cabozantinib (XL184) in patients with renal cell cancerAnn Oncol20142581603160824827131
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [webpage on the Internet]Cabozantinib-s-malate or Sunitinib Malate in Treating Patients with Previously Untreated Locally Advanced or Metastatic Kidney Cancer Available from: https://clinicaltrials.gov/ct2/show/NCT01835158Accessed June 17, 2016
   Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [webpage on the Internet]Cabozantinib-s-malate and Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Genitourinary Tumors Available from: https://clinicaltrials.gov/ct2/show/NCT02496208Accessed June 17, 2016
   Google Scholar
• SmithDCSmithMRSweeneyCCabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialJ Clin Oncol201331441241923169517
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [webpage on the Internet]Cabozantinib-s-malate or Sunitinib Malate in Treating Patients with Previously Untreated Locally Advanced or Metastatic Kidney Cancer Available from: https://clinicaltrials.gov/ct2/show/NCT01835158Accessed June 17, 2016
   Google Scholar
• ClinicalTrials.gov [webpage on the Internet]Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Available from: https://clinicaltrials.gov/ct2/show/NCT02761057Accessed June 17, 2016
   Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar